Postpartum Hemorrhage Treatment Devices Market to Reach USD 1.74 Billion by 2035, Growing at 5.7% CAGR

​The postpartum hemorrhage treatment devices market size will be USD 998.2 million in 2025. According to Fact.MR analysis, the industry will expand with a CAGR of 5.7% and reach USD 1,740.6 million by the year 2035. The rising incidence of atonic uterus PPH, especially in developing countries, along with growing institutional deliveries, is one of the main drivers of growth.

Advances in technology in minimally invasive care and expanding access to gynecologic care are also fueling the need for efficient management tools for PPH. Postpartum hemorrhage remains a leading cause of maternal mortality, especially in low- and middle-income countries.

Though oxytocin and uterotonic medications have been the mainstay of early intervention for decades, expanding access to device-based interventions such as balloon tamponades, non-pneumatic anti-shock garments (NASG), and intrauterine vacuum-induced devices is radically altering treatment outcomes. They offer rapid, low-cost management of hemorrhage when drugs are not effective or unavailable. More government focus on maternal health, particularly through global health programs, is raising awareness and deployment of treatment for PPH.

For More Insights into the Market, Request a Sample of this Report:https://www.factmr.com/connectus/sample?flag=S&rep_id=7644

Market Overview

PPH remains a leading cause of maternal mortality, particularly in low- and middle-income countries. Traditional interventions like uterotonic drugs are being supplemented by device-based treatments, including uterine balloon tamponades (UBTs), non-pneumatic anti-shock garments (NASGs), and intrauterine vacuum-induced devices. These devices offer rapid, cost-effective management of hemorrhage, especially when drugs are ineffective or unavailable .​

Key Devices and Innovations

Uterine Balloon Tamponades (UBTs)

UBTs, such as the Bakri balloon, are widely used for controlling PPH. The Bakri balloon, a silicone catheter with a 500 mL capacity, has shown success rates of up to 90% in managing PPH . These devices are endorsed by organizations like the World Health Organization (WHO) and the International Federation of Gynecology and Obstetrics (FIGO).​

Non-Pneumatic Anti-Shock Garments (NASGs)

NASGs are low-technology first-aid devices used to treat hypovolemic shock. They work by returning blood to vital organs, stabilizing women until they can receive definitive care. Studies have shown that NASGs can significantly reduce blood loss, maternal mortality, and the need for emergency hysterectomy .​

Prefilled Injection Systems

Prefilled injection systems, like the Uniject, facilitate the rapid administration of uterotonic drugs. These systems are particularly useful in low-resource settings, ensuring timely intervention to prevent PPH.​

Regional Insights

North America

North America holds a significant share of the PPH treatment devices market, driven by advanced healthcare infrastructure and increased awareness. The U.S. market alone was estimated at USD 278.3 million in 2022 . The FDA's approval of devices like the Jada System, which showed a 94.3% success rate in controlling PPH, further boosts market growth .​

Europe

Europe accounts for 30% of the global market, with countries like Germany, France, and the UK leading in the adoption of advanced maternal care solutions. Over 60% of European healthcare facilities have integrated UBTs and AI-driven hemorrhage monitoring systems into standard obstetric care .​

Asia-Pacific

The Asia-Pacific region is the fastest-growing market, driven by investments in maternal healthcare infrastructure in countries like China, India, Japan, and South Korea. Government and NGO initiatives are promoting affordable treatment solutions to address the high incidence of untreated PPH .​

Challenges and Opportunities

Challenges

High costs of advanced PPH treatment devices pose a significant barrier, especially in developing nations. Over 35% of healthcare facilities in these regions lack access to advanced maternal care solutions. Additionally, regulatory constraints and compliance issues delay the entry of new devices into the market

Opportunities

The integration of AI-based maternal monitoring solutions presents a significant growth opportunity. AI-driven blood loss monitoring systems can detect hemorrhage 30% faster than manual methods. The rise of smart obstetric monitoring tools and wearable health technology contributes to better patient monitoring and early hemorrhage prevention .​

Get Customization on this Report for Specific Research Solutions-https://www.factmr.com/connectus/sample?flag=S&rep_id=7644

Future Outlook

The PPH treatment devices market is poised for continued growth, driven by technological advancements, increased awareness, and supportive government initiatives. The focus on developing cost-effective, user-friendly devices will be crucial in addressing the challenges faced in low-resource settings. As healthcare systems worldwide prioritize maternal health, the adoption of advanced PPH treatment devices is expected to rise significantly.

Explore More Related Studies Published by Fact.MR Research:

Medical Marker Bands Market

https://www.factmr.com/report/4364/medical-marker-bands-market

Bone Wax Market

https://www.factmr.com/report/bone-wax-market

Gamma Ray-based Robots Market

https://www.factmr.com/report/gamma-ray-based-robots-market

Collagen and HA-based Biomaterials Market

https://www.factmr.com/report/collagen-and-ha-based-biomaterials-market

Breast Surgery Retractors Market

https://www.factmr.com/report/4678/breast-surgery-retractors-market

Manual Resuscitators Market

https://www.factmr.com/report/manual-resuscitators-market

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

About Fact.MR:

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.